Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system.
Saved in:
| Title: | Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system. |
|---|---|
| Authors: | Fu X; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; National Medical Products Administration Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China., Zeng D; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Cancer Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.; Foshan Key Laboratory of Translational Medicine in Oncology, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China., Li M; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Wu J; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Yang Y; Clinical Pharmacy Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; National Medical Products Administration Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China., Mao Q; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Qiu W; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Huang X; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Fang Y; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Jiang L; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Hu P; Department of Obstetrics and Gynecology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China., Wu J; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China., Liao W; Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.; Cancer Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China.; Foshan Key Laboratory of Translational Medicine in Oncology, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China. |
| Source: | Expert opinion on drug safety [Expert Opin Drug Saf] 2026 Jul; Vol. 25 (7), pp. 1309-1317. Date of Electronic Publication: 2025 Feb 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1744-764X |
|---|---|
| DOI: | 10.1080/14740338.2025.2471512 |
